Indapamide regresses, but transdermal clonidine does not regress, left ventricular hypertrophy in hypertensive diabetic patients

American Journal of Cardiology

Volumn 77, Issue 6, 1996, Pages B20-B22

  Tan, Stanley A ^a,b   Berk, Lee S ^a   Tan, Linda G ^a  

^a LOMA LINDA UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ENDORPHIN; BRADYKININ; CATECHOLAMINE; CLONIDINE; INDAPAMIDE;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DIABETES MELLITUS; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0030051147     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)89235-1     Document Type: Conference Paper

References (26)

1. Blumenthal HT, Alex M, Goldenberg S. A study of lesions of the intramural coronary by branches in diabetes mellitus. Arch Pathol 1960;70:27-42.
2. Factor SM, Okun EM, Minase T. Capillary microaneurysms in human diabetic heart. N Engl J Med 1980;302:384-388.
3. Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990; 82:848-355.
4. Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986;105:173-178.
5. Kannel WB, Wilson PWF, Zhang T. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991;121:1268-1273.
6. Messerli FH, Oren S, Grossman E. Left ventricular hypertrophy and antihypertensive therapy. Drugs 1988;35(suppl 5):27-33.
7. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14:203-209.
8. B. Dustan HP. Calcium channel blockers. Potential medical benefits and side effects. Hypertension 1989;13(suppl I):137-140.
9. Williams GH. Converting enzyme inhibitors in the treatment of hypertension. N Engl J Med 1989;319:1517-1525.
10. Gifford RW, Borazanian RA. Traditional first-line therapy. Overview of medical benefits and side effects. Hypertension 1989;13(suppl I):119-124.
11. Sahn DJ, DeMaria A, Kisslo J, Weyman A. Recommendations regarding quantitation in m-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978;58:1072-1083.
12. Schiller N, Skioldebrand C, Schiller E, Mavroudis C, Silverman N, Rahimtoola S, Lipton M. Canine left ventricular mass estimation by two-dimensional echocardiography. Circulation 1983;68:210-216.
13. Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. Am J Cardiol 1983;51:171-176.
14. Lukman LF, Berk LS, Tan SA. Enalapril normalizes depressed bradykinin levels in essential hypertension and hypertensive diabetics. J Invest Med 1995;43: 322A.
15. Tan SA, Tan LG, Berk LS. Beta-endorphin stimulatory effects of ramipril in diabetics. Clin Res 1992;40:22A.
16. Blumenthal HT, Alex M, Goldenberg S. A study of lesions of the intramural coronary by branches in diabetes mellitus. Arch Pathol 1960;70:27-42.
17. Van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation 1990;82:848-855.
18. Tarazi RC. Regression of left ventricular hypertrophy by medical treatment: present status and possible implications. Am J Med 1983;75(suppl 3A):80-86.
19. Lavie CJ, Ventura HO, Messerli FH. Regression of increased left ventricular mass by antihypertensives. Drugs 1991;42:945-961.
20. McMahon FG, Michael R, Ryan JR, LaCoste WS, Jain A. Regression of left ventricular hypertrophy in nineteen hypertensive patients treated with clonidine for eighteen months: a prospective study. In: Weber MA, Drayer JIM, Kolloch R, eds. Low Dose Oral and Transdermal Therapy of Hypertension. Darmstadt, Germany: Steinkopff Verlag, 1985:81-85.
21. Drayer JIM, Gardin JM, Weber MA, Aronow WS. Changes in ventricular septal thickness during diuretic therapy. Clin Pharmacol Ther 1982;32:283-288.
22. Wollam GL, Hall WD, Porter VD, Douglas MB, Unger DJ, Blumenstein BA, Cotsonis GA, Knudtson ML, Felner JM, Schlant RC. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. Am J Med 1983;75:100-110.
23. Komajda M, Klimczak K, Boutin B, Brackman F, Guez D, Grosgogeat Y. Effects of indapamide on left ventricular mass and function in systemic hypertension with left ventricular hypertrophy. Am J Cardiol 1990;65(suppl):37H-42H.
24. Sami M, Haichin R. Regression of left ventricular hypertrophy in hypertrension with indapamide. Am Heart J 1991;122:1215-1218.
25. Senior R, Imbs JL, Bory M, Amabile G, Denis B, Zannad F, De Luca N, Marchegiano R, Lahiri A, Raftery EB, Guez D, Chic M. Indapamide reduces hypertensive left ventricular hypertrophy: an international multicenter study. J Cardiovasc Pharmacol 1993;22(suppl 6):S106-S111.
26. Cury CL, Robinson H, Brown R, Olivan J, Sami M, Honost G, Ruddy TD, Balazovjech I, Tousek F, Galinier F, Mariani M, Guez D, Regression of left ventricular hypertrophy in 130 patients with essential hypertension: results of 6 month treatment with indapamide. (Abstr.) Am J Hypertens 1995;8:196A(D44).